Compare FXNC & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FXNC | STXS |
|---|---|---|
| Founded | 1907 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.6M | 201.6M |
| IPO Year | 2012 | 2004 |
| Metric | FXNC | STXS |
|---|---|---|
| Price | $26.17 | $2.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 67.6K | ★ 413.8K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | $7,717,000.00 | ★ $29,346,617.00 |
| Revenue This Year | $12.21 | $24.21 |
| Revenue Next Year | $2.93 | $29.83 |
| P/E Ratio | $19.73 | ★ N/A |
| Revenue Growth | ★ 7.40 | N/A |
| 52 Week Low | $18.26 | $1.54 |
| 52 Week High | $28.89 | $3.59 |
| Indicator | FXNC | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 42.95 | 41.71 |
| Support Level | $25.35 | N/A |
| Resistance Level | $26.49 | $2.49 |
| Average True Range (ATR) | 0.77 | 0.12 |
| MACD | -0.18 | 0.02 |
| Stochastic Oscillator | 17.67 | 20.57 |
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. Key revenue is generated from Community Banking.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.